This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
by Zacks Equity Research
Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -17.14% and +33.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $5.81, moving 2.35% from the previous trading session.
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
by Zacks Equity Research
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.95, marking a -5.71% move from the previous day.
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
by Ahan Chakraborty
Recursion Pharmaceuticals and Relay Therapeutics both leverage their respective AI drug discovery platforms to potentially develop novel therapeutic candidates.
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.43, signifying a -1.68% move from its prior day's close.
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
by Ahan Chakraborty
Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Recursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Recursion Pharmaceuticals (RXRX) Rises Higher Than Market: Key Facts
by Zacks Equity Research
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $5.52, indicating a +2.41% shift from the previous trading day.
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock
by Ahan Chakraborty
RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
by Ahan Chakraborty
RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.72, marking a +2.24% move from the previous day.
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
by Zacks Equity Research
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
by Ahan Chakraborty
Recursion Pharmaceuticals axes three drug programs after weak study data, but shifts focus to more promising candidates like REC-4881 to regain ground.
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
by Zacks Equity Research
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $5.27, denoting a +1.15% move from the preceding trading day.
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
by Ahan Chakraborty
Recursion Pharmaceuticals is transforming drug discovery with AI-driven RecursionOS, slashing costs and boosting development speed.
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) reached $5.03 at the closing of the latest trading day, reflecting a -6.85% change compared to its last close.
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $5.03, representing a -1.57% change from its previous close.
Why Is Zoetis (ZTS) Up 8.1% Since Last Earnings Report?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?
by Ahan Chakraborty
Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.
Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock
by Ahan Chakraborty
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.